Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T
The Lancet, Volume 344, No. 8919, Year 1994
Notification
URL copied to clipboard!
Description
Summary. Efficacy of the Haemophilus influenzae type b (Hib) conjugate vaccine PRP-T (Pasteur-Merieux) was evaluated in a controlled community intervention study in the Oxford region, UK. PRP-T was offered to infants from May 1, 1991 in three of the region's eight districts and from July 1, 1991, in a fourth district. It was given by separate injection in addition to the standard diphtheria, tetanus, and pertussis vaccine according to an accelerated 2, 3, and 4 month schedule without a booster dose in the second year of life. By October 1, 1992, more than 90% of infants in vaccine districts had received at least one dose of PRP-T. None of the infants given three doses had developed Hib infection, whereas 11 infections occurred in the control population (vaccine efficacy 100%, 95% Cl 80-100%). Intention-to-treat analysis also showed a high estimate of efficacy for the vaccine (90%, 50-99%). Follow-up of study children until November 1, 1993, has shown only 1 vaccine failure in an infant, and no invasive infections in those older than 1 year (average age 22 months). PRP-T vaccine had high protective efficacy with an accelerated immunisation schedule. Furthermore, the vaccine appears to remain protective through the second year of life without a booster dose. These findings provide encouragement for use of PRP-T in the Expanded Programme of Immunisation. © 1994.
Authors & Co-Authors
Booy, Robert
United Kingdom, Oxford
Oxford University Hospitals Nhs Foundation Trust
Moxon, E. Richard
United Kingdom, Oxford
Oxford University Hospitals Nhs Foundation Trust
Mayon-White, Richard T.
United Kingdom, Oxford
Oxford University Hospitals Nhs Foundation Trust
Slack, Mary Paulina Elizabeth
United Kingdom, Oxford
Oxford University Hospitals Nhs Foundation Trust
Carpenter, Lucy J.
United Kingdom, Oxford
Radcliffe Infirmary
United Kingdom, Oxford
University of Oxford Medical Sciences Division
Haworth, Elizabeth A.
Unknown Affiliation
Statistics
Citations: 125
Authors: 6
Affiliations: 4
Identifiers
Doi:
10.1016/S0140-6736(94)91400-1
ISSN:
01406736
Research Areas
Maternal And Child Health
Study Design
Randomised Control Trial
Cross Sectional Study
Cohort Study